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ABSTRACT
Background: The neuregulin-1 (NRG1) gene has been identified as a candidate gene
for schizophrenia. NRG1 signals mainly through the ErbB4 receptor. Previous studies
have shown that NRG1 and the ErbB4 receptor are dysregulated in the brains of
schizophrenia patients. This suggests that the expression of NRG1-ErbB4 could respond
to treatment with antipsychotic drugs. This study aimed to investigate the effects of
short-term and chronic antipsychotic treatment on the expression of NRG1 isoforms and
ErbB4 receptors.
Methods: Female Sprague-Dawley rats were treated orally with three antipsychotic
drugs, haloperidol (0.3 mg/kg/day), olanzapine (1.5 mg/kg/day), aripiprazole (2.25
mg/kg/day), or vehicle for either 1 week or 12 weeks. Western blotting was performed
to examine the expression levels of three sub-types of NRG1 including type I (105kDa),
III (83kDa) and 40 kDa isoform and its ErbB4 receptors in the prefrontal cortex (PFC),
the cingulate cortex (CG), the hippocampus, and the hypothalamus.
Results: In the 12-week treatment groups, chronic treatments with aripiprazole and
haloperidol significantly decreased the expression of ErbB4 receptors and all three subtypes of NRG1 isoforms in the PFC. NRG1-type I expression was also reduced by longterm treatment with aripiprazole in the CG. In the hypothalamus, 12-week treatment
with aripiprazole decreased protein levels of ErbB4 receptors and NRG1-type III and 40
kDa isoforms; and long-term treatment with haloperidol reduced 40 kDa isoform
expression. On the other hand, 1-week treatments with these antipsychotics had fewer
effects on the expression of NRG1 isoforms and ErbB4 receptors, olanzapine slightly
increased the protein level of NRG1-type I and III in the hippocampus, while
haloperidol increased the expression of NRG1-type III in the hypothalamus.
Conclusion: Short-term and chronic treatment with typical and atypical antipsychotics
have differential effects on regulating the expression of NRG1-ErbB4 in various brain
regions, which may contribute to development of new antipsychotic therapeutics for
schizophrenia patients.
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CHAPTER 1: LITERATURE REVIEW
1.1

Introduction

Schizophrenia is a complicated mental disease. Genetic factors are believed to play an
important role in the development of schizophrenia. Many genes have been identified as
candidate genes for schizophrenia. The neuregulin-1 (NRG1) gene is one of the
strongest of the susceptibility genes identified. NRG1 signals through the ErbB4
receptor. NRG1-ErbB4 signalling performs critical functions in the nervous system, and
has been found to be impaired in schizophrenia patients.

To date, many antipsychotic drugs have been invented and used in the clinic to treat
schizophrenia symptoms. Studies showed that many antipsychotic drugs can reverse the
dysfunctions of NRG1-ErbB4 signalling in schizophrenia subjects; and also
demonstrated that the expression of NRG1 isoforms and ErbB4 receptors can be altered
by treatment with antipsychotic drugs.

This chapter will review the pathophysiology of schizophrenia, abnormal NRG1-ErbB4
signalling in schizophrenia, and the altered expression of NRG1 isoforms and ErbB4
receptors after treatment with different antipsychotic drugs.

1.2

What is Schizophrenia?

Schizophrenia is a persistent, chronic, severe and disabling mental disorder
characterised by abnormalities in the perception of reality, affecting approximately 1%
of the general world population (Lisman et al., 2008; Perälä et al., 2007). The term
“schizophrenia” was first used by Swiss psychiatrist Eugen Bleuler in 1911 from the
Greek roots schizein ("to split") and phrēn, phren- ("mind"), roughly meaning "splitting
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of the mind", because patients who developed schizophrenia seemed to vacillate
between normal and abnormal states (Hansen and Atchison, 2000). To date, many
variations in the manifestation of schizophrenia have been identified, however, the exact
aetiology of schizophrenia is still unclear (Sawa and Snyder, 2002).

Schizophrenia symptoms are clinically characterised by positive symptoms, negative
symptoms and cognitive deficits (Lisman et al., 2008). Patients who develop positive
symptoms usually manifest abnormal thoughts and behaviours, including auditory
hallucinations, delusions, disorganised and unusual thinking and speech, as well as
disorganised or catatonic behaviour (Bennett, 2008).

Negative symptoms represent the loss or absence of normal traits or abilities. Patients
with negative symptoms usually experience a reduction of emotional responsiveness,
flat or blunted affect, poverty of speech, inability to experience pleasure, memory
impairment, and lack of motivation (Bodkin et al., 1996).

Cognitive deficits mainly include memory deficits, attenuated attention processes, and
executive functioning impairment. Patients display deficits in immediate and delayed
recall, verbal and spatial memory, sequencing, organisation and flexibility (Gopal and
Variend, 2005).

1.3

The Neurotransmitter Hypotheses for Schizophrenia

Abnormal neurotransmission has been identified in various systems in schizophrenia.
There are two mainstream theories on the pathophysiology of schizophrenia: the
dopamine hypothesis and the glutamate hypothesis.
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1.3.1

Dopamine Hypothesis

In the past 50 years, studies on the aetiology of schizophrenia have mainly focused on
the dopaminergic system, because the dopamine receptors are the principle target of
antipsychotic drugs. The dopamine hypothesis of schizophrenia postulates a
hyperactivity of dopaminergic transmission at the dopamine D2 receptor in the
mesencephalic projections to the striatum (Carlsson, 1988). This hypothesis is
supported by the observation of the effects of drugs such as amphetamine and cocaine
that can increase the levels of dopamine in the brain, and induce schizophrenia-like
symptoms in normal subjects (Seeman, 1980). It is also supported by the clinical effects
of chlorpromazine and other related antipsychotic drugs, such as fluphenazine and
haloperidol, that can treat positive symptoms of schizophrenia, diminishing the synaptic
activities of dopamine neurons by potently blocking the dopamine D2 receptors (Creese
et al., 1976; Seeman et al., 1976).

1.3.2

Glutamate Hypothesis

In recent years, glutamatergic system dysfunction became more central to schizophrenia
research. The glutamate hypothesis of schizophrenia postulates that the N-methyl-Daspartate (NMDA) receptor hypofunction in the prefrontal cortex (PFC) and
hippocampus may be implicated in the pathophysiology of schizophrenia (Coyle, 1996;
Olney and Farber, 1995). The glutamate hypothesis was originally based on clinical
observation that the anaesthetics phencyclidine and ketamine induced positive and
negative symptoms and cognitive deficits resembling schizophrenia in normal subjects
through non-competitively antagonising the NMDA subtype of glutamate receptor
(Duncan et al., 1999; Krystal et al., 1994; Morris et al., 2005). In addition, the glutamate
hypothesis is also supported by genetic findings pointing to a hypofunction of the
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glutamatergic system. For example, the metabotropic glutamate receptor 3 (mGluR3)
gene that encodes mGluR3 glutamate receptors has been reported to be associated with
schizophrenia (Harrison and Weinberger, 2005).

1.4

Neuropathological Abnormalities in Schizophrenia

Schizophrenia is associated with brain structural abnormalities in individuals (McCarley
et al., 1999). Reduction of total brain volume has been reported in first-episode
schizophrenia, where patients have not begun treatment with antipsychotic medication,
and therefore the brain structures are not affected by antipsychotic drugs (Lawrie and
Abukmeil, 1998; McCarley et al., 1999; Morgan et al., 2007). Enlargement of cerebral
ventricles, such as the lateral and third ventricles, have been almost uniformly observed
(Lawrie and Abukmeil, 1998). Longitudinal neuroimaging studies have demonstrated
that gray matter volume decreases and the fluid compartment increases in the lateral and
third ventricles over the course of schizophrenia (Gur et al., 1998; Morgan et al., 2007).
Additionally, neuropathological changes have been found in several brain regions that
are related to the aetiology of schizophrenia, including the PFC, the cingulate cortex
(CG), the hippocampus, and the hypothalamus.

1.4.1

Abnormalities in the Prefrontal Cortex

The PFC is involved in planning complex cognitive behaviours, predicting future events,
human general intelligence, personality expression, executive functions and in
governing social behaviours (Miller and Cohen, 2001). Studies have suggested that
dysfunction of the PFC (most notably the dorsolateral PFC) is associated with the
development of schizophrenia (Bunney and Bunney, 2000), causing symptoms of poor
attention and conceptual disorganization (Servan-Schreiber et al., 1996). A magnetic
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resonance imaging study suggested that disturbance of the dorsolateral PFC is
implicated in both dysfunction of working memory and the pathophysiology of
schizophrenia (Perlstein et al., 2001). The NMDA receptor hypofunction, which is
believed to be involved in the development of schizophrenia, affects several
corticolimbic brain regions including the PFC (Lewis and Lieberman, 2000). Evidence
showed that the NMDA receptors are present in high levels in the prefrontal cortex, and
relative proportions of mRNAs for the NR2 subunit family are changed in the prefrontal
cortex of schizophrenic brains, compared with controls (Ruppin, 2000).

1.4.2

Abnormalities in the Cingulate Cortex

The CG is implicated in the regulation of emotions, moods, and organisation of
cognitive functions (e.g. problem solving and decision making) (Guidotti et al., 2000;
Teasdale et al., 1999). Thus, it has been proposed that dysfunction in the CG is relevant
to the pathophysiology of schizophrenia (Baiano et al., 2007). Post-mortem studies have
shown decreased axonal connections, reduced neuronal density, and altered neuronal
somal size in the CG of schizophrenic patients (Lisman et al., 2008). Hypofunction of
the glutamatergic system also occurred in the CG of schizophrenia patients. Previous
studies in our group, using quantitative autoradiography, showed that the NMDA
receptors were up-regulated in both the anterior and posterior CG of schizophrenia
patients compared with controls, indicating a reduction of glutamatergic transmission
that may result in a compensatory up-regulation of the NMDA receptor binding in the
CG (Newell et al., 2005; Zavitsanou et al., 2002).

1.4.3

Abnormalities in the Hippocampus
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The functions of the hippocampus include forming new long-term memory and spatial
navigation (Cooke and Bliss, 2006). Abnormalities of the hippocampus were found to
be relevant to the pathophysiology of schizophrenia. Bilateral reduction in the volume
of the hippocampal formation has been observed in schizophrenic subjects in a postmortem study (Harrison, 1999). Luts et al. provided evidence that pyramidal cells were
disoriented in the CA1 - CA3 subfields of the hippocampus in schizophrenia subjects
(Luts et al., 1998). There is also evidence suggesting that biochemical changes,
including glutamatergic and GABAergic dysfunction in the hippocampus, are
associated with schizophrenia (Lewis and Lieberman, 2000). Gao et al. found a
reduction in the NMDA receptor subunits NR1 in some hippocampal subregions in
schizophrenia patients compared with the healthy subjects (Gao et al., 2000).

1.4.4

Abnormalities in the Hypothalamus

The hypothalamus, connecting to nearly every part of the central nervous system
including the cortex and hippocampus, regulates drives, affect, the autonomic and
endocrine systems (Williams et al., 2001). Many functions of the hypothalamus were
found to be abnormal in schizophrenia subjects. In schizophrenia patients, mammillary
bodies in the hypothalamic region were found to be larger than in the controls (Briess et
al., 1998). Goldstein also showed enlarged hypothalamic volumes in schizophrenia
patients compared with the healthy controls (Goldstein et al., 2007). In addition, a study
using monozygotic and same-sex dizygotic twin pairs with schizophrenia to compared
with healthy control twin pairs, found hypothalamic volume in the schizophrenia twins
relatively decreased compared with healthy controls, suggesting genetic factors may
play a role in controlling hypothalamic volume (Koolschijn et al., 2008).
1.5

The Genetic Factors that Cause Schizophrenia
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1.5.1

Genetic Factors as a Primary Cause of Schizophrenia

Considerable evidence from family, twin, and adoption studies suggests that genetic
factors are strongly implicated in the pathophysiology of schizophrenia, although
environmental factors may also play an important role in the development of
schizophrenia (Miyamoto et al., 2003). Owen and colleagues have suggested that
schizophrenia is primarily a complex genetic disorder, with estimates of approximately
80% heritability (Owen et al., 2002). The general population life time prevalence is
about 1%, however relatives of schizophrenic individuals have a higher risk of
schizophrenia and related disorders. The rates of developing schizophrenia in family
members are associated with the levels of their biological relationship with
schizophrenia patients; and the family members with higher levels of shared genes with
schizophrenia patients have greater risk of developing schizophrenia (Gottesman, 1991).
For example, third-degree relatives (e.g. first cousins) of schizophrenia patients share
about 12.5% of their genes, and they display a risk of about 2% to develop
schizophrenia. Second-degree relatives (e.g. grandchildren, half-siblings) share about 25%
of their genes and show risks of around 5%. First-degree relatives (e.g. parents, siblings,
children, and dizygotic twins) share about 50% of their genes and have risks of from 6%
to 17%. Monozygotic twins share 100% of their genes, and have a 48% risk of
developing schizophrenia and related disorders (Gottesman, 1991).
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Figure 1.11 Rates of developing
d
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effects on receptors (e.g. GRM3, CHRNA7, DAOA), signal transduction (e.g. RGS4),
and regulation of plasticity and synaptogenesis (e.g. NRG1, DTNBP1, DISC1, PPP3C)
(Harrison and Weinberger, 2005). There are also some genes that directly link with the
dopaminergic (e.g. COMT) and the GABAergic systems (e.g. NRG1) (O'Donovan et
al., 2003). However, the possibility and the manner of interactions between genes and
the functional interactions between proteins encoded by these genes are still not fully
understood. The present study focused on theNRG1 gene and its proteins.

Table 1.1 Schizophrenia susceptibility genes and strength of the evidence.

Genes

Strength of evidence (level zero to five)
for association with schizophrenia

DTNBP1

five

NRG1

five

COMT

four

RGS4

three

GRM3

three

DISC1

three

G72

three

DAAO

two

PPP3CC

one

CHRNA7

one

PRODH2

one

Akt1

one

CHRNA7 = cholinergic receptor nicotinic alpha 7; COMT = catechol-O-methyl transferase;
DAOA = D-amino acid oxidase activator; DISC1 = disrupted-in-Schizophrenia 1; DTNBP1 =
Dysbindin; GRM3 = glutamate receptor metabotropic 3; NRG1 = Neuregulin-1; PPP3C =
protein phosphatase 3; PRODH = proline dehydrogenase (oxidase) 1; RGS4 = regulator of G
protein signalling-4.

(Modified from: Harrison and Weinberger, 2005)
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1.6
1.6.1

NRG 1 Gene as a Susceptible Gene in Schizophrenia
NRG1 Gene and Its Isoforms

The neuregulins are a family of four genes (NRG1-4) encoding proteins containing an
epidermal growth factor (EGF)-like motif. Each of the protein types has a distinct
amino-terminal region. The EGF-like domain is located in the membrane-proximal
region of the extracellular domain (Mei and Xiong, 2008). The NRGs isoforms signal
by stimulating membrane-associated tyrosine kinases related to the EGF receptors
through the EGF-like domain (known as ErbB receptors), in which the NRG1 isoforms
are best-characterized (Harrison and Law, 2006).

Table 1.2 Genetic effects of schizophrenia susceptibility genes.

Genes

Functions

GRM3
G72
DAAO

Neurotransmission

CHRNA7

(Receptors, Signal Transduction)

RGS4
PRODH
PPP3CC
Akt1
NRG1

DTNBP1

Plasticity
Synaptogenesis

DISC1
COMT

Dopaminergic System

CHRNA7 = cholinergic receptor nicotinic alpha 7; COMT = catechol-O-methyl transferase;
DAOA = D-amino acid oxidase activator; DISC1 = disrupted-in-Schizophrenia 1; DTNBP1 =
Dysbindin; GRM3 = glutamate receptor metabotropic 3; NRG1 = Neuregulin-1; PPP3C =
protein phosphatase 3; PRODH = proline dehydrogenase (oxidase) 1; RGS4 = regulator of G
protein signalling-4.

(Modified from: Harrison and Weinberger, 2005)
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The NRG1 gene has been identified by Stefansson and colleagues as a risk gene in
Icelandic and Scottish populations with schizophrenia, indicating a twofold higher
relative risk, and this finding has been replicated in subsequent studies (Stefansson et al.,
2003; Stefansson et al., 2002; Williams et al., 2003; Yang et al., 2003). The human
NRG1 gene is located at chromosome 8p13 (Holmes et al., 1992). It has more than 20
exons and several large introns, spanning approximately 1.4 mega bases (Harrison and
Law, 2006). NRG1 generates six types of protein (I-VI), classified according to their
distinct amino-terminal sequences (Figure 1.2). All six types of NRG1 isoforms have an
EGF-like domain. types I, II, IV and V have an immunoglobulin (Ig)-like domain
between the N-terminal sequence and the EGF domain, with or without the spacer
region (S), whereas the N-terminal-specific region of types III and VI is connected
directly to the EGF domain. Additionally, there are four types of the linker regions, also
contributing to forming variants. All the above parts ─ NRG1 sequences (except type III
sequence), the EGF domain, the spacer region and the linker region, form the extracellular regions of NRG1 molecules. In the type III isoforms, this sequence contains a
transmembrane domain (TMn), which is different from other sequences. The
cytoplasmic tails form the intra-cellular regions of NRG1 molecules. Finally, a Cterminal transmembrane domain (TMc) is located between the two regions. Because of
different types of specific-protein sequences, the EFG-like domains, linkers and
cytoplasmic tails, there are about 30 NRG1 isoforms, including the proteins: NEU
differentiation factor (NDF), heregulin, glial growth factor (GGF), acetylcholinereceptor-inducing activity (ARIA) and sensory and motor neuron-derived factor (SMDF)
(Harrison and Law, 2006; Mei and Xiong, 2008; Meyer et al., 1997).
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Figure 1.22 Structure of NRG1 isofforms. (Reprrinted by perrmission from
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1.7
1.7.1

Antipsychotic Drugs
Typical Antipsychotics

Typical antipsychotics, discovered in the 1950s, known as first-generation or
conventional antipsychotics, were the first effective antipsychotic drugs to treat
schizophrenia. The first typical antipsychotic to enter clinical use was chlorpromazine
(Thorazine), which was initially developed as an antihistamine and was accidently
found to be effective to ameliorate the positive symptoms in schizophrenia. After the
serendipitous discovery of chlorpromazine, a number of typical antipsychotics were
discovered and used clinically to treat psychosis, especially schizophrenia, including
fluphenazine (Prolixin), haloperidol (Haldol), thioridazine (Mellaril), trifluoperazine
(Stelazine), pipotiazine (Piportil) and perphenazine (Trilafon). Typical antipsychotics
elicit their clinical efficacy through diminishing the synaptic activities of dopamine by
potently and specifically blocking the dopamine D2 and D3 receptors (e.g. haloperidol in
Table 1.3) (Creese et al., 1976; Seeman et al., 1976).

Although typical antipsychotics are effective in treating positive symptoms in
schizophrenia, they have fewer effects on negative symptoms or cognitive deficits (Agid
et al., 2008). Additionally, because of the blockade of the dopamine D2 receptors in the
extrapyramidal system, typical antipsychotics can cause a series of side effects,
especially extrapyramidal effects (EPS), including movement disorders (e.g., Parkinson
syndrome and akathisia) and irreversible tardive movements (e.g., dyskinesias,
dystonias) which occur in nearly 25% of chronically treated patients (Tarsy and
Baldessarini, 2006).
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Table 1.3 Receptor affinities of main typical and atypical antipsychotic drugs. All values are
reported as Ki (nM).
Receptor

Haloperidol

Olanzapine

Aripiprazole

Clozapine

Risperidone

D2

0.7

11

0.45

126

4

D3

2

49

0.8

473

10

D4

3

27

44

35

9

5-HT1A

2600

>7100

4.4

875

210

5-HT2A

45

4

3.4

16

0.5

5-HT2C

1500

23

15

16

25

α adrenergic

6

19

57

7

0.7

H1

440

7

61

6

20

M1

>1500

1.9

>10,000

1.9

>10,000

D2 = dopamine2; D3 = dopamine3; D4 = dopamine4; 5-HT1A = serotonin1A; 5-HT2A = serotonin2A;
5-HT2C = serotonin2C; H1 = histamine1; M1 = muscarinic1.
(Modified from: DeLeon et al., 2004)

1.7.2

Atypical Antipsychotics

In the 1960s, the first atypical antipsychotic drug (also known as second-generation
antipsychotics), clozapine (Clozaril) was developed and was used in the clinic in the
1970s. After clozapine, other new atypical antipsychotic drugs, including risperidone
(Risperdal), olanzapine (Zyprexa), quetiapine (Seroquel), ziprasidone (Geodon), and
aripiprazole (Abilify), have been developed and clinically used in the treatment of
schizophrenia.

Atypical antipsychotics are as effective as typical antipsychotics in treating positive
symptoms, and are uniquely effective in alleviating negative symptoms (Danion et al.,
1999; Ho et al., 1999) and cognitive symptoms (Cleghorn et al., 1990) in schizophrenia
which are not affected by typical antipsychotics. Additionally, they cause EPS less
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commonly than do typical antipsychotics, although they may cause weight gain and
metabolic side effects (Mathews and David, 2007).

Atypical antipsychotics have different affinities not only with dopaminergic receptors,
but also with many other G-protein couple receptors (GPCRs) (Table 1.3), including the
serotonin [5-hydroxy-tryptamine (5-HT)] system (e.g. olanzapine and risperidone), the
α adrenergic system (e.g. clozapine, and risperidone), the histamine H1 receptors (e.g.
olanzapine and risperidone), and the muscarinic M1 receptors (e.g. olanzapine) (Levine
et al., 2003; Mathews and David, 2007; Schwieler et al., 2008). Most of the atypical
antipsychotics share a common attribute, acting on the dopamine D2 receptors and the
serotonin 5-HT2A,2C receptors to achieve their clinical efficacy (Duncan et al., 1999;
Farah, 2005). However, their exact underlying mechanisms are still poorly studied; and
it is also unclear whether the actions at other receptors (e.g. α adrenergic and histamine
H1) alone or in combination account for the clinical efficacy of atypical antipsychotics
(Duncan et al., 1999).

1.7.3

Aripiprazole ─ A Unique Atypical Antipsychotic

Aripiprazole (Abilify), a dihydrocarbostyril (quinolinone) derivative, is a newly US
Food and Drug Administration (FDA) approved antipsychotic. It is the sixth atypical
antipsychotic drugs introduced to the market. Aripiprazole is sometimes also called a
“third-generation antipsychotic” since it exhibits unique mechanisms of action. For
example, aripiprazole possesses partial dopaminergic agonism for both postsynaptic D2
receptors and presynaptic autoreceptors, partial agonism for the 5-HT1A receptors and
antagonism at the 5-HT2A receptors (Burris et al., 2002; DeLeon et al., 2004) (Table
1.3), a so-called dopamine and serotonin stabilizer. The abilities of aripiprazole to
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stabilize the dopaminergic and serotonergic systems may be associated with its
favourable clinical efficacy and tolerability profile (Burris et al., 2002).

Unlike other antipsychotics, aripiprazole causes very few side effects. For example,
aripiprazole has been associated with minimal weight gain and metabolic changes
(Mathews and David, 2007). Additionally, aripiprazole results in EPS at a very low rate
(Mathews and David, 2007; Uzun et al., 2005). However, whether these definitive
advantages are associated with dopamine partial agonism are not fully understood.

1.8

Expression of NRG1 Isoforms and ErbB4 Receptors are altered by
Antipsychotic Treatments

1.8.1

Effects of Antipsychotic Treatments on the Expression of NRG1 Isoforms

In a Finnish population study, Kampman and colleagues found that NRG genotype
distributions are different between responders and non-responders to typical
antipsychotics, suggesting that clinical drug treatments should change according to
NRG genotype distributions (Kampman et al., 2004). There were several studies
including animal and clinical studies, directly investigating NRG1 isoform expression
under different antipsychotic treatments (Table 1.4). First, in an animal study, four
weeks’ administration of the typical antipsychotic haloperidol increased the expression
of NRG1 isoforms and administration of the atypical antipsychotic clozapine reduced
the expression of NRG1 isoforms in the rat PFC. Four-week treatment with haloperidol
and clozapine both increased NRG1 protein expression in the hippocampus, which was
not consistent with the changes in the PFC. Additionally, 4-week treatment with the
atypical antipsychotic risperidone increased the protein level of NRG1 isoforms in the
hippocampus, but not in the PFC (Wang et al., 2008).
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In the clinic, expression of NRG1 proteins was studied in schizophrenia patients who
normally receive very long-term (from months to years) and multiple medications. The
expression of NRG1 (including the protein level and its mRNA) were found to be
abnormal in schizophrenia patients compared with the healthy controls. Hashimoto et al.
reported an increased expression of NRG1-type I isoform; and decreased type II/I and
type II/III ratios in the PFC of schizophrenia patients, which may mean relatively
decreased expression of type II isoform (Hashimoto et al., 2004). Additionally, Law et
al. found that the levels of mRNA for NRG1-type I were elevated both in the PFC and
in the hippocampus of schizophrenia patients (Law et al., 2006). Another study
demonstrated that the expression of NRG1-type I isoform was decreased in the
prefrontal Brodmann areas (BA) 9, 10 and the hippocampus, and the expression of
NRG1-type II isoform increased in BA10 of schizophrenia patients (Parlapani et al.,
2008). Moreover, in another study, NRG1 protein expression was shown to be increased
in human brain aggregates after being exposed to clozapine for three weeks; however,
the expression of NRG1 proteins did not change following exposure to haloperidol
(Chana et al., 2009).

NRG1 (the proteins and its mRNA) expression was also studied clinically in peripheral
systems. For example, a study reported that NRG1 mRNA expression in peripheral
blood lymphocytes (PBLs) of first-episode patients was lower than that in the control
group at first; however after treatment with the antipsychotic drugs risperidone and
quetiapine for two weeks, NRG1 mRNA expression of PBLs significantly increased
compared to the levels before the antipsychotic drug therapies (Zhang et al., 2008).
Petryshen et al. also found that the expression of NRG1-type I (β-3) and type III (SMDF)
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in PBLs increased in schizophrenia patients after treatment with various antipsychotic
drugs (Petryshen et al., 2005).
Table 1.4 Chronic studies on the effects of antipsychotics on the expression of NRG1 isoforms.

Studies

Treatments

Duration

Main results

Wang et
al., 2008

Haloperidol,
Clozapine,
Risperidone

4 weeks

(1) Haloperidol promoted NRG1 expression;
clozapine reduced NRG1 expression in
the rat PFC.
(2) Haloperidol and clozapine increased the
protein levels of NRG1in the rat
hippocampus.
(3) Risperidone increased the expression of
NRG1 in the rat hippocampus.

Chana et
al., 2009

Clozapine
Haloperidol

3 weeks

NRG-1 expression in normal human brain
aggregates up-regulated when exposed to
clozapine.

Chronic

(1) NRG1-type I expression increased in
schizophrenia patients.
(2) Type II/I and type II/III ratios in the PFC
of schizophrenia patients decreased.
(1) Expression of NRG1-type I was
decreased in BA 9, 10 and the
hippocampus of schizophrenia patients.
(2) Expression of type II increased in BA10.

Hashimoto
et al., 2004

Multiple

Parlapani
et al., 2008

Multiple

Chronic

Law et al.,
2006

Multiple

Chronic

NRG1-type I was elevated in the PFC and the
hippocampus in schizophrenia patients.

Zhang et
al., 2008

Risperidone,
Quetiapine

2 weeks

NRG1 expression of PBLs in schizophrenia
patients increased after therapies.

Petryshen
et al., 2005

Multiple

Chronic

Expression of NRG1-type I and type III increased
in schizophrenia patients

1.8.2

Effects of Antipsychotic Treatment on Expression of ErbB4 receptors

Expression of ErbB4 receptors was also reported to be changed after administrations of
antipsychotic drugs (Table 1.5). An animal study reported that after a 4-week treatment
of normal rats, haloperidol promoted ErbB4 receptor protein expression in the rat PFC;
haloperidol and clozapine significantly increased the protein levels of ErbB4 receptors
in the hippocampus; and risperidone also increased the expression of ErbB4 receptor
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proteins in the hippocampus (Wang et al., 2008). Moreover, a clinical study showed that
the expression of ErbB4 receptors isoforms that contain the C-terminal cytoplasmic tails
(CYT)-1 domain was significantly increased in the dorsolateral PFC of schizophrenia
patients (Silberberg et al., 2006).
Table 1.5 Studies on the effects of antipsychotics on the expression of ErbB4 receptors.

Studies

Treatments

Wang et
al., 2008

Haloperidol,
clozapine,
risperidone

Silberberg
et al., 2006

Multiple

1.8.3

Main results
(1) Haloperidol promoted ErbB4 protein expression in the
rat PFC.
(2) Haloperidol and clozapine increased the proteins levels
of ErbB4 receptors in the rat hippocampus.
(3) Risperidone increased the expression of ErbB4
receptors in the rat hippocampus.
ErbB4 receptors isoforms that contain the CYT-1 domain are
over expressed in the dorsolateral PFC of schizophrenia
patients.

Summary

Among a number of susceptibility schizophrenia genes, the NRG1 gene is one of the
strongest candidate genes for schizophrenia. Previous studies have demonstrated that
antipsychotic drugs can influence the expression of NRG1 and ErbB4 receptors (Hahn
et al., 2006; Kampman et al., 2004; Rimer et al., 2005; Wang et al., 2008). However, the
relationship between the expression of NRG1 and ErbB4 receptors and antipsychotic
treatment has not been fully explored. First, few antipsychotics were used in previous
studies. Whether other antipsychotics with distinct pharmacological properties could
affect the expression of NRG1 and its ErbB4 receptors is unknown. Secondly, previous
studies have not fully established the underlying molecular mechanisms of how
antipsychotic treatments influence the expression of NRG1 isoforms and ErbB4
receptors. Lastly, protein expression after treatment with antipsychotics in some
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schizophrenia-related brain regions has not been measured. The present study has
focused on these topics.

1.9
1.9.1

Aims and Hypotheses
Aims

The present study aimed to investigate whether treatment with one typical antipsychotic
drug (haloperidol) and atypical antipsychotic drugs (olanzapine and aripiprazole) have
differential effects on the expression of NRG1 isoforms and ErbB4 receptors in
different brain regions.
1.9.2

Hypotheses

We hypothesized that compared to the control group, the expression of NRG1 isoforms
and ErbB4 receptors would be significantly altered in the brain regions related to the
pathophysiology of schizophrenia, following short-term and chronic treatment with
three antipsychotic drugs (haloperidol, olanzapine, and aripiprazole).

The differential effects of short-term and long-term antipsychotic treatments on the
expression of NRG1 isoforms and ErbB4 receptors in these brain regions are examined
in Chapter 3 and Chapter 4, respectively.
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CHAPTER 2: GENERAL METHODS AND MATERIALS
2.1

Animals and Housing

A total number of 48 female Sprague Dawley rats (9 weeks old; 220–250g) were
obtained from the Animal Resource Centre (Perth, Australia). Rats were housed in
individual cages under environmentally controlled conditions (temperature 22°C, light
cycle from 07:00 to 19:00 h and dark cycle from 19:00 to 07:00 h), with ad libitum
access to water and standard laboratory chow. All rats were allowed one week to
acclimatise to the new surroundings before any experiment began. All experimental
procedures were approved by the Animal Ethics Committee, University of Wollongong,
and complied with the Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes (Seventh Edition, 2004).

2.2

Treatment Protocol

After arrival, all rats were divided into eight treatment groups (n=6). The outline of this
study is shown in Figure 2.1. Rats were administered 2.25 mg/kg/day aripiprazole
(Bristol-Meyers Squibb, USA), 1.5 mg/kg/day olanzapine (Eli Lilly, USA), 0.3
mg/kg/day haloperidol (Sigma Aldrich, USA), or vehicle. The daily dosage was divided
into three equal amounts, and all rats were treated three times per day (06:00, 14:00, and
22:00 h) orally by specially prepared food pellets. This method has been used
successfully in previous studies (Huang-Brown and Guhad, 2002) including in our
laboratory (Han et al., 2008; Huang et al., 2006). Specified measurements of drugs and
1% chocolate in standard laboratory chow matrix were mixed and made into pellets
(~3mm) (for composition: see Table 2.1). Rats were administered pellets without drugs
for one week prior to the commencement of the experiment. Each rat was then
administered three pellets per time and three times per day, and observed throughout the
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feeding peeriods to ensure compleete consump
ption of thee pellets by each rat. Since rats aree
naturally attracted to
o chocolatee, this tech
hnique is an
n efficient method off oral drugg
administraation.

ARI = aripiprazole; HA
AL = haloperridol; OLAN
N = olanzapin
ne.
Figure 2.1 Flowchart of
o the experim
mental design of the pressent study.

Table 2.1 Composition
C
n of chocolatee pellets.
Ingredientts

Chocolaate

Cornn
starchh

Sucrosse

Casein
n

Fibre

Minerals

Vitamins

Percentagge

6.25%
%

30.75%
%

30.75%
%

15.50%
%

6.50%

8.50%

1.75%
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2.2.1

Choices of Antipsychotic Drugs

The first drug in the present study was haloperidol. Haloperidol is a representative
typical antipsychotic drug which has been used in a number of studies to compare the
mechanisms of typical and atypical antipsychotics and is also widely used in the clinic
to treat mainly positive schizophrenic symptoms. Haloperidol is very efficient in
treating hallucinations, delusions, aggressiveness, impulsiveness and states of
excitement, due to a potent blockade of dopaminergic receptors in the mesocortex and
the limbic system of the brain (Ayd, 1978; Settle and Ayd, 1983).

The second drug used, olanzapine, is a widely used atypical antipsychotic favoured
because of its efficacy and tolerance by patients. Olanzapine is able to alleviate both
positive and negative symptoms of schizophrenia and other psychotic disorders.
Olanzapine can potently bind to a broad range of receptors, including the serotonin 5HT2,3,6, receptors and the dopamine D1,4 receptors (Mathews and David, 2007).
Olanzapine also shows a low affinity for histamine H1, cholinergic muscarinic M1 and
α1-adrenergic receptors (Komossa et al., 2009) (Table 1.3 in Chapter 1).

The third drug used in the present study was the new atypical antipsychotic drug,
aripiprazole. A range of studies have shown that aripiprazole is as effective as
haloperidol in improving positive symptoms of schizophrenia (Young et al., 2009) and
is also able to treat negative symptoms (Davies et al., 2004). As described in Chapter 1,
section 1.6.3, aripiprazole possesses a unique pharmacological profile. It produces
partial agonism for the dopamine D2 and the serotonin 5-HT1A receptors, and
antagonism for the 5-HT2A receptors (Burris et al., 2002; Jordan et al., 2002; Jordan et
al., 2003), which is different from typical and other atypical antipsychotic drugs.
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2.2.2

Antipsychotic Drug Dosages

The drug dosages selected in the present study have been used in several previous
studies and have been shown to be behaviourally effective. For example, several studies
have used haloperidol at a dose of 0.3 mg/kg (Pouzet et al., 2003; Wiley, 2008); further,
previous studies also utilised doses of olanzapine at doses from 1.2 (Arjona et al., 2004;
Huang et al., 2006) to 2.0 mg/kg (Cooper et al., 2005); and, aripiprazole has been used
at a dose of 2.5 mg/kg (Bruins Slot et al., 2005). Furthermore, all of these selected doses
have exhibited a D2 occupancy exceeding 70% in the rat brain, higher than the accepted
threshold for antipsychotic effects (Kapur et al., 2003; Natesan et al., 2005; Natesan et
al., 2006). Previous studies in our lab have also shown that the doses of these drugs used
in the present study were able to affect central receptor systems relative to their
pharmacological properties, suggesting that at such doses, these drugs can reach their
pharmacological efficacy (Han et al., 2006; Huang et al., 2006).

2.3

Histology

Forty-eight hours after the last drug treatment, all rats (48 in short-term groups, 48 in
long-term groups) were sacrificed using CO2 asphyxiation followed by decapitation. All
rats were sacrificed between 07:00 and 09:00 h, to minimize the possible circadianinduced variations of protein expression. Brains were immediately removed after death,
frozen in liquid nitrogen and stored at -80°C. Four sites of the brain were dissected,
including the PFC, the CG, the hippocampus and the hypothalamus (Figure 2.2). The
tissues collected were frozen in liquid nitrogen and stored at -80°C until use.
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Prefrontaal
Cortex

C
Cingulate Cortex

A (Brregma 3.7mm)
m)

B (Bregma 0.77mm)
pus
Hippocamp

Hypothalamus
H

C (Bregmaa -2.3mm)

Figure 2.2 Histography
y of the four brain region
ns. (Adapted from: Paxinoos and Watso
on, 1998)

Tissue obttained from
m individual rats was ho
omogenised
d in ice-coldd homogeniising bufferr
[9.8ml NP40
N
cell lysis buff
ffer (Invitrogen, Cam
marillo, CA
A, USA), 100µl β-Glycerophhosphate (50mM; Invittrogen), 33..3µl PMSF (0.3M; Siggma-Aldrich
h, St Louis,,
MO, USA
A), and 100
0µl Proteasee Inhibitor Cocktail (S
Sigma-Aldriich)]. Due to its shortt
half-life, the
t PMSF was addedd immediateely before use.
u The deegradation of proteinss
from eachh sample waas inhibitedd by both th
he Proteasee Inhibitor C
Cocktail an
nd PMSF inn
the homoogenising buffer. The samples were
w
also homogenise
h
ed quickly to preventt
degradatioon of proteeins due too increased temperature, and theen centrifug
ged for 100
minutes att 200,000 × g at 4°C. T
The supernaatants that contained thhe required proteins
p
forr
the presennt study werre aliquotedd to four tubes and storeed at -80°C until requirred.
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2.4
2.4.1

Immunoblotting Analysis
Measurements of the Total Protein Concentrations

The total protein concentrations of each sample were quantified using the Bio-Rad DC
Protein Assay (500-0116, Bio-Rad, Hercules, CA, USA) with bovine serum albumin
(BSA) as a standard. First, working reagent A` was prepared by adding 20μl of reagent
S (from the Bio-Rad DC Protein Assay) to each ml of reagent A (also from the Bio-Rad
DC Protein Assay). Then 5 dilutions of BSA containing from 0.2 mg/ml to about 1.2
mg/ml protein were prepared to make a standard curve (a standard curve was made each
time the assay was performed). 5μl of standards and samples were pipeted into a clean,
dry microtiter plate. 25μl of reagent A' was added into each well, then 200μl of reagent
B (from the Bio-Rad DC Protein Assay) was added into each well. If there were bubbles
in the well, they were removed with a clean, dry pipet tip. The wavelength of the
microplate reader, a Power Wave X340 (Bio-Tek Instruments, Inc., Winooski, VT), was
set to 750nm. After 15 minutes, the microtiter plates were placed in the microplate
reader, the absorbances were read by comparing to the stardard curve to calculate
protein concentration.

2.4.2

Immunoblotting

Homogenised brain samples containing 10µg of protein were firstly heated at 95 °C in
the loading buffer [950µl laemmli buffer (Bio-Rad) and 50µl β-mercapethanol (SigmaAldrich)] for five minutes to denature the proteins. Then the samples were loaded into
CRTGEL4-12% Bis-Tris Polyacrylamide Gels (Bio-Rad) together with Precision Plus
Dual Colour Protein Standards (Bio-Rad). The samples were subjected to
electrophoresis in 1x XT-MOPS running buffer [50ml 20x XT-MOPS running buffer
(Bio-Rad) and 950ml distilled water] at 200V for fifty minutes. The various proteins in
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each sample were separated on the gel by molecular weight. The separated proteins
were then transferred electrophoretically onto a non-specific protein binding
polyvinylidene difluoride (PVDF) membrane (Bio-Rad) in the ice cold transfer buffer
[150ml 10x Tris/Glycine Buffer (Bio-Rad), 300ml cold methanol and 1050ml distilled
water] at 100V for one hour. The PVDF membranes were incubated in the TrisBuffered Saline-Tween (TBST) (Sigma-Aldrich) solution containing 5% BSA for one
hour at room temperature to block the remaining non-specific protein binding pores on
the PVDF membrane. Each membrane was then incubated overnight at 4°C in the
primary antibodies (described in Chapter 3 and Chapter 4, respectively) diluted in TBST
and 1% BSA buffer. On the second day, each membrane was washed three times with
TBST for five minutes and incubated for one hour at room temperature with horseradish
peroxidase-conjugated goat anti-rabbit (1:3000; Millipore, Billerica, MA, USA)
secondary antibodies diluted in TBST buffer containing 1% BSA. The membranes were
then each washed three times with TBST for five minutes.

The proteins of interest were visualized by reacting the membranes with the ECL
(Enhanced Chemiluminescence) Plus Western Blotting Detection Reagents kit (GE Life
Sciences, Piscataway, NJ, USA) for sixty seconds, and exposing them to Kodak
BioMax film (Sigma-Aldrich).

After exposure, the membranes were washed three times with TBST for five minutes
each and incubated with mouse anti-actin primary polyclonal antibody (1:10000;
Millipore) for one hour at room temperature. Then the membranes were reacted with
horseradish peroxidase-conjugated rabbit anti-mouse secondary antibody (1:3000;
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Millipore) for one hour at room temperature. The β-actin protein levels were then
measured by using the ECL system.

2.4.3

Quantification

The films were developed using Kodak GBX developer and fixer (Sigma-Aldrich).
Developed films were then scanned using a GS-800 Imaging Densitometer (Bio-Rad).
The optical densities of the bands of interest were quantified with the Quantity-1
software (Bio-Rad). The ErbB4 receptor protein was quantified at 185 kDa,
representing the full length of ErbB4 protein molecule (Hahn et al., 2006); The NRG1
isoforms protein were quantified at 105 kDa (Frenzel and Falls, 2001) and 83 kDa
(Wang et al., 2001), representing the full length of NRG1-type I and N-terminal
fragment of NRG1-type III, respectively. The 40 kDa isoform of NRG1 was also
quantified, which is possibly a fragment of NRG1-type II isoform protein based on
manufacturer’s instructions, however, the evidence is not decisive, needing further
confirmation. The β-actin protein was quantified at 46 kDa. All results were normalized
by taking the value of the vehicle group as 100%. Two independent experiments were
performed.

2.5

Statistical Analysis

All data was analysed using the SPSS 17.0 program (SPSS, Chicago, IL, USA) and
expressed as means ± S.E.M. The protein expression in each brain region was analysed by
two-way Analysis of Variance (ANOVA) (Period × Treatment). Post-hoc multiple
comparisons (Dunnet t test) were followed to compare each drug treatment group with
controls. Pearson Correlation was used to analyse the relationships among the
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expression of NRG1 isoforms and ErbB4 receptors if they were significantly changed in
the same brain region.

Page 30

CHAPTER 3: THE EFFECTS OF ANTIPSYCHOTICS ON THE EXPRESSION
OF NRG1 ISOFORMS

3.1

Introduction

As reviewed in Chapter 1, NRG1 isoforms play critical roles in the nervous system. The
NRG1 gene was also identified to be one of the strongest candidate genes for
schizophrenia (Stefansson et al., 2002). Further, it is believed that the dysfunction of
NRG1-ErbB4

signalling

is

closely

related

to

the

abnormalities

of

many

neurotransmission systems that are implicated in the pathophysiology of schizophrenia
(Harrison and Law, 2006).

Many studies, including animal and human studies, have shown that expression of
NRG1 isoforms can respond to treatments with antipsychotic drugs (summarised in
Chapter 1, section 1.8.1). These studies only tested a few antipsychotic drugs
(risperidone, quetiapine, haloperidol, and clozapine); and there are many other
antipsychotic drugs on the market now, which possess distinct and complicated
pharmacological properties. Therefore, whether and how these antipsychotic drugs
affect the expression of NRG1 isoforms in different brain regions needs to be
systematically explored.

In this experiment, the effects of three antipsychotic treatments on the expression of
three sub-types of NRG1 were investigated. Among the six NRG1 sub-types, the action
properties of type IV, type V and type VI NRG1s are less well-known, therefore, only
the isoforms containing type I, II, III NRG1 protein sequences were specified and
measured.
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Additionally, three antipsychotic drugs were used to treat animals in this experiment;
haloperidol, olanzapine and aripiprazole. Their pharmacological properties and dosages
were briefly discussed in Chapter 2, section 2.1.1 and 2.1.2, respectively.

3.2
3.2.1

Methods and Materials
Animal Treatment and Tissue Preparations

Materials and procedures as outlined in Chapter 2, section 2.1 and 2.2.

3.2.2

Immunoblotting

Western Blotting experiments were described in Chapter 2, section 2.4.2. The primary
antibody for this study was anti-NRG1 (SC-348 Santa Cruz Biotechnology, Santa Cruz,
CA, USA). The dilution of the antibody was 1:200. Based on our pre-experiments, the
time of exposure to Kodak BioMax film was three minutes. The other antibodies used in
this study including the secondary antibody and β-actin antibodies have also been
described in Chapter 2, section 2.4.2. The exposure time for the β-actin antibody was
twenty seconds.

3.2.3

Quantification

In this experiment, the expression of NRG1 isoforms in the four brain sites was
examined using the immunoblotting technique. NRG1 isoforms displayed up to 12
immunoreactive bands, which is consistent with other studies that have used the same
NRG1 antibody (SC-348, Santa Cruz) (Bernstein et al., 2006; Chong et al., 2008;
Savonenko et al., 2008). According to the manufacturer’s indication, of these 12 bands,
three bands were quantified in the present study – the 105 kDa band (NRG1-type I
isoform), the 40 kDa band, and the 83 kDa band (NRG1-type III isoform) as discussed
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in Sectionn 2.4.3. Thee other imm
munoreactiv
ve bands were not quaantified since they aree
beyond the scope of the
t present sstudy.

3.2.4 Staatistical Anaalysis
First, NRG
G1 protein levels dataa were corrrected based on their correspond
ding β-actinn
levels to control thee sample-looading variations in protein conncentration. Then thee
or the four brain regioons was determined byy
differencees in NRG1 isoform exxpression fo
two-way ANOVA
A
(P
Period × Treeatment), reespectively.. Multiple ccomparisons (Dunnet t
test) follow
wed to com
mpare each ddrug treatm
ment with the control. W
When the p value from
m
the Dunneet t test waas less thann 0.05, the difference between thhe drug treatment andd
control waas considereed as signifi
ficant.

3.3

Results

3.3.1 Exxpression off NRG1-typpe I in the Fo
our Brain Regions
R
Examples of the imaages of thee Western blot
b experiment show
wing the exp
pression off
NRG1-typpe I and β-actin are shoown in Figure 3.1.
Arripiprazole

Halo
operidol

Olanzapiine

Control

n in the prefr
frontal cortex
x
Figure 3.1 An examplee of image off NRG1-typee I expression

E
of
o NRG1-tyype I in the Prefrontal
P
Cortex
C
3.3.1.1 Expression
A two-waay ANOVA revealed siignificant efffects of Treeatment (F33,48 = 5.287,, p = 0.005))
and Periood (F1,48 = 101.651, p < 0.001)) on NRG1
1-type I exxpression in
n the PFC..
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However, there was no
n significaant interactiion between
n the two faactors (F3,488 = 1.563, p
= 0.219).

Figure 3.22 shows the expression of NRG1-ttype I in thee PFC after tthe three an
ntipsychoticc
treatmentss. Post-hoc analysis shoowed that, compared with
w the conntrol, both aripiprazole
a
e
treatment (-53%, p = 0.007) andd haloperid
dol treatmen
nt (-43%, p = 0.046) significantlyy
e
in the 12--week treattment grouup. Howev
ver, proteinn
decreased protein expression
week treatm
ment with olanzapine
o
(p
( = 0.310)) was not significantlyy
expressionn after 12-w
changed. In
I addition,, in the 1-w
week treatm
ment groups,, there was no significcant changee
between any
a drug treaatment grouup and the control.
c

Figure 3.22 The Expression of N
NRG1-type I in the prefrrontal cortexx. *p<0.05 compared
c
too
control; **p<0.01 comp
pared to conttrol.
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3.3.1.2 Expression
E
of
o NRG1-tyype I in the Cingulate Cortex
C
A significcant effect of
o Period (F
F1,48 = 169.631, p < 0..001) was rrevealed by a two-wayy
ANOVA analysis on
o NRG1-tyype I exprression in the CG, w
whereas thee effect off
Treatmentt did not sh
how signifiicance (F3,448 = 1.434, p = 0.251)); however, there wass
significantt interaction
n between P
Period and Treatment
T
(F
F3,48 = 3.0449, p = 0.043
3).
Twelve-w
week treatmeent with ariipiprazole significantly
s
y decreasedd protein ex
xpression off
NRG1-typpe I compaared with thhe control (-32%, p = 0.039) (FFigure 3.3). However,,
protein exxpression after
a
12-weeek treatmeent with bo
oth haloperi
ridol (p = 0.207) andd
olanzapinee (p = 0.83
35) did not significanttly change NRG1-type
N
e I expressiion. On thee
other handd, after the 1-week treeatment, th
here was no
o significantt change beetween anyy
drug treatm
ment group and the conntrol.

Figure 3.33 The Exprression of N
NRG1-type I in the cing
gulate cortexx. *p<0.05 compared
c
too
control.
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3.3.1.3 Expression
E
of
o NRG1-tyype I in the Hippocamp
H
pus
A two-waay ANOVA revealed siignificant efffects of Treeatment (F33,48 = 3.800,, p = 0.020))
and Periodd (F1,48 = 12
29.040, p < 0.001) on NRG1-type
N
I expressioon in the hip
ppocampus..
However, there was no significcant interacttion betweeen Period aand Treatmeent (F3,48 =
1.485, p = 0.238).

(
3.44) showed that 1-week treatm
ment with olanzapinee
Post-hoc analysis (Figure
N
e I (+66%, p = 0.045), whereas noo
significanttly increaseed the proteiin level of NRG1-type
significantt change waas observedd in the 12-w
week treatm
ment groups.

Figure 3..4 The expression of NRG
G1-type I in the hippocam
mpus. *p<0.005 compared
d to control.

3.3.1.4 Expression
E
of
o NRG1-tyype I in the Hypothalam
H
mus
A significcant effect of
o Period (F
F3,48 = 110.435, p < 0..001) was rrevealed by a two-wayy
ANOVA analysis
a
on
n NRG1-typpe I expresssion in the hypothalam
h
mus, whereaas the effectt
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of Treatm
ment did no
ot show siggnificance (F1,48 = 1.860, p = 00.157). Theere was noo
significantt interaction
n between thhe two facto
ors (F3,48 = 1.509, p = 00.232).

Post-hoc analysis
a
(Fiigure 3.5) ddemonstrateed no signifficant changges between
n each drugg
treatment group and
d the controol in eitherr 1-week trreatment grroups or 12-treatmentt
groups. However,
H
theere were treends toward
ds significan
nce betweenn short-term
m treatmentt
with halopperidol and the controol (+68%, p = 0.074), and betweeen long-term
m treatmentt
with aripipprazole and
d the controll (-33%, p = 0.064).

Figure 3.55 The expression of NRG
G1-type I in the
t hypothalaamus.

Regions
3.3.2 Exxpression off 40 kDa isooform of NR
RG1 in the Four
F
Brain R
Examples of the imaages of the W
Western blot experimeent showingg the expression of 400
kDa isoforrm of NRG1 and β-actiin are show
wn in Figure 3.6.
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Aripiprazolee

Haloperidol

Olanzappine

Control

Figure 3.66 An example of the imagges of Expreession of 40 kDa
k isoform of NRG1.

3.3.2.1 Expression
E
of
o 40 kDa issoform of NRG1
N
in thee Prefrontal Cortex
A two-waay ANOVA revealed a significant effect of Peeriod (F1,48 = 562.916, p < 0.001),,
and signifficant interaaction betweeen Period and Treatm
ment (F3,48 = 8.536, p < 0.001) onn
the expresssion of 40 kDa
k isoform
m of NRG1 in the PFC
C, whereas tthe effect off Treatmentt
(F3,48 = 1.6669, p = 0.1
195) did nott reach sign
nificance.

wed a signifficant decreease in thee
As describbed in Figure 3.7, poost-hoc anaalysis show
protein exxpression in
n the 12-weeek treatmen
nt groups of aripiprazoole (-61%, p = 0.003),,
and haloperidol (-60%
%, p = 0.0009) compareed with the control. Hoowever, aftter 12-weekk
on was not significantlyy changed (p
( = 0.156)..
treatment with olanzaapine, proteein expressio
In additionn, analysis of
o the 1-weeek treatmen
nt group did
d not show any significcant changee
between each
e
drug treeatment grooup and the control.
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Figure 3.77 The expreession of 400 kDa isoform of NRG1 in the preffrontal cortex. **p<0.01
compared to
t control.

3.3.2.2 Expression
E
of
o 40 kDa issoform of NRG1
N
in thee Cingulate Cortex
A two-way ANOVA showed thaat the effectt of Period was
w significcant (F1,48 = 210.968, p
< 0.001) on
o the exprression of 440 kDa isofform of NR
RG1 in the CG, but th
he effect off
Treatmentt (F3,48 = 0.5
564, p = 0.6643) did nott reach signiificance. In addition, th
here was noo
significantt interaction
n between P
Period and Treatment
T
(F
F3,48 = 2.21 8, p = 0.105
5).

As shownn in Figure 3.8, no siggnificant diffference waas found inn either 1-w
week or 12-week treaatment grou
ups in the ppost-hoc an
nalysis. How
wever, therre were nottable trendss
towards siignificant diifferences bbetween thee aripiprazolle treatmentt group and the controll
(-35%, p = 0.068), an
nd between the haloperridol treatm
ment group aand the con
ntrol (-37%,,
p = 0.053)) in the 12-w
week treatm
ment groups.
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Figure 3.88 The expression of 40 kD
Da isoform of
o NRG1 in the
t cingulatee cortex.

3.3.2.3 Expression
E
of
o 40 kDa issoform of NRG1
N
in thee Hippocam
mpus
A two-waay ANOVA revealed siignificant efffects of Treeatment (F33,48 = 4.119,, p = 0.015))
and Periodd (F1,48 = 454.831, p < 0.001) on the expresssion of 40 kkDa isoform
m of NRG1
in the hipppocampus. However, tthere was no
n significan
nt interactioon between Period andd
Treatmentt (F3,48 = 0.2
220, p = 0.8882).

Post-hoc analysis (Figure 3.9) indicated that
t
there was
w no signnificant chaange in thee
expressionn of 40 kDaa isoform off NRG1 in either
e
short--term treatm
ment groupss or chronicc
treatment groups.
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Figure 3.99 The expression of 40 kD
Da isoform of
o NRG1 in the
t hippocam
mpus.

3.3.2.4 Expression
E
of
o 40 kDa issoform of NRG1
N
in thee Hypothalaamus
A two-waay ANOVA demonstratted that therre were sign
nificant effe
fects of both
h Treatmentt
(F3,48 = 111.765, p < 0.001)
0
and P
Period (F1,448 = 301.246
6, p < 0.0011) on the ex
xpression off
40 kDa issoform of NRG1 in tthe hypothaalamus. On
n the other hand, the interactionn
between Period
P
and Treatment was also shown
s
to be significannt (F3,48 = 3.458, p =
0.028).

As presennted in Fig
gure 3.10, compared with the control,
c
12--week treattment withh
aripiprazoole (-66%, p < 0.001) aand haloperridol (-35%,, p = 0.025)) significan
ntly reducedd
the expresssion of 40 kDa isoform
m of NRG1
1 in the hyp
pothalamus, whereas th
here was noo
significantt change am
mong each drug treatm
ment and th
he control ggroups afterr short-term
m
treatment.
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Figure 3.10 The exp
pression of 440 kDa isoform of NR
RG1 in the hypothalam
mus. *p<0.055
t control; **
*p<0.01 com
mpared to con
ntrol
compared to

3.3.3 Exxpression off NRG1-typpe III in the Four Brain Regions
Examples of the imaages of thee Western blot
b experiment show
wing the exp
pression off
NRG1-typpe III and β--actin are shhown in Fig
gure 3.11.
Aripiprazole
A

Haloperidol

Olanzappine

Control

pe III Expresssion.
Figure 3.11 An example of image oof NRG1-typ

E
of
o NRG1-tyype III in thee Prefrontall Cortex
3.3.3.1 Expression
A two-waay ANOVA
A showed tthat there were signifficant effeccts of Perio
od (F1,48 =
246.706, p < 0.001)) and Treaatment (F1,448 = 8.099,, p < 0.00 1) on NRG
G1-type IIII
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expressionn in the PF
FC. In addittion, there was
w also significant innteraction between
b
thee
two factorrs (F3,48 = 4.655, p = 0. 009).

Similar too the expresssion of NR
RG1-type I and 40 kD
Da isoform in the PFC
C, post-hocc
analysis (F
Figure 3.12
2) showed a significan
nt decrease in protein expression
n in the 12-week treattment group
p between tthe aripipraazole treatm
ment group ((-59%, p = 0.002) andd
the controol, and betw
ween the haaloperidol treatment
t
group
g
(-43%
%, p = 0.03
33) and thee
control. There
T
was no
n change inn protein expression
e
between
b
thee olanzapine treatmentt
group andd the controll (p = 0.6022). Also, anaalysis of thee 1-week treeatment gro
oups did nott
show any significant changes am
mong drug trreatments and the contrrol groups.

Figure 3.112 The expreession of NR
RG1-type IIII in the preffrontal cortexx. *p<0.05 compared
c
too
control; **pp<0.01 comp
pared to conttrol
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3.3.3.2 Expression
E
of
o NRG1-tyype III in thee Cingulate Cortex
A two-waay ANOVA
A revealed that there was a sign
nificant effe
fect of Period (F1,48 =
109.589, p < 0.001) on NRG1--type III Ex
xpression in
n the CG. H
However, th
he effect off
Treatmentt (F3,48 = 1.307, p = 0.289) diid not reacch significaance. In ad
ddition, thee
interactionn between Period
P
and T
Treatment was
w not foun
nd to be siggnificant (F3,48
= 0.767,,
3
p = 0.521)).

Similar to the expresssion of 40 kkDa isoform
m in the CG,, Figure 3.1 3 shows no
o significantt
differencee of NRG1-ttype III exppression after 1-week and
a 12-week
ek treatmentt. However,,
there was a trend tow
wards a siggnificant diifference beetween the aripiprazole treatmentt
t 12-week
k treatment group.
group andd the controll (-30%, p = 0.091) in the

Figure 3.13 The expresssion of NRG
G1-type III in
n the cingulaate cortex.
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3.3.3.3 Expression
E
of
o NRG1-tyype III in thee Hippocam
mpus
A two-waay ANOVA revealed siignificant effects
e
of Peeriod (F1,48 = 242.007, p < 0.001))
and Treattment (F3,448 = 7.6144, p = 0.001) on NR
RG1-type IIII expresssion in thee
hippocamppus. Howev
ver, interacttion betweeen Period an
nd Treatmeent was nott significantt
(F3,48 = 1.3395, p = 0.2
264).

a
(Figure 3.14)) demonstraated that 1--week treattment with olanzapinee
Post-hoc analysis
significanttly increaseed the proteiin level of NRG1-type
N
III (+92%,, p = 0.005)). However,,
no significcant changee was revealled in the 12
2-week treatment groupps.

Figure 3.14 The expresssion of NRG
G1-type III in the hippocampus. *p<00.05 compareed to controll.

E
of
o NRG1-tyype III in thee Hypothalaamus
3.3.3.4 Expression
A two-waay ANOVA
A showed siignificant efffects of bo
oth Treatmeent (F3,48 = 7.351, p =
III expression in thee
0.001) annd Period (F
F1,48 = 56.3398, p < 0.001)
0
on NRG1-type
N
Page 455

hypothalam
mus. The in
nteraction bbetween Perriod and Treeatment (F33,48 = 4.172,, p = 0.014))
was also demonstrate
d
ed to be signnificant.

There wass a significant increas e after 1-w
week treatment with haaloperidol (+87%,
(
p=
0.014) (F
Figure 3.15). Additioonally, thee expressio
on of NR
RG1-type III
I in thee
hypothalam
mus was deecreased byy 64% after treating wiith aripiprazzole for 12 weeks (p =
0.001)

Figure 3.115 The exprression of N
NRG1-type III
I in the hy
ypothalamuss. *p<0.05 compared
c
too
control; **pp<0.01 comp
pared to conttrol.

3.4

Disccussion

In the preesent study
y, the expreession of NRG1-type
N
I, type III and 40 kD
Da isoform
m
(possibly type II) were
w
investiggated in th
he PFC, thee CG, the hippocamp
pus and thee
hypothalam
mus in ratt brains affter treatmeent with antipsychoti
a
ic drugs aripiprazole,,
haloperidool and olanzzapine for eeither 1 weeek or 12 weeks.
w
This study was the first too
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examine the effects of 12-week treatment with antipsychotic drugs on the expression of
NRG1 isoforms. The present study was also the first to investigate how aripiprazole
affects the expression of NRG1 isoforms.

The results indicate that 1-week treatment with antipsychotics has few effects on NRG1
expression (Table 3.1). In the PFC, none of the three sub-types of NRG1 were
significantly affected by any antipsychotic treatment, nor were the NRG1 levels in the
CG significantly changed. However, the olanzapine treatment significantly increased
the protein levels of NRG1-type I and type III in the hippocampus; with no effect on 40
kDa isoform. In the hypothalamus, treatment with haloperidol also tended to promote
the expression of NRG-type I and type III, although this effect on NRG-type I
expression was not statistically significant. The expression of 40 kDa isoform of NRG1
in the hypothalamus was not affected by any antipsychotic treatments.
Table 3.1 Significant changes in NRG1 isoform expression after 1-week treatment.
Prefrontal
Cingulate cortex
Hippocampus
Hypothalamus
cortex
Aripiprazole

-

-

-

-

Haloperidol

-

-

-

type III ↑

Olanzapine

-

-

type I, III ↑

-

By comparison, 12-week treatment with antipsychotics displayed more significant
effects on expression of NRG1 isoforms (Table 3.2). First, both aripiprazole and
haloperidol significantly inhibited NRG1-type I, type III and 40 kDa isoform expression
in the PFC. In addition, aripiprazole also decreased the protein levels of NRG-type I in
the CG; haloperidol showed a trend to decrease the expression of 40 kDa isoform in the
CG. In the hypothalamus, the expression of type III and 40 kDa isoform was reduced by
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treatment with aripiprazole; haloperidol treatment also decreased 40 kDa isoform; in
addition, the expression of NRG1-type I tended to be decreased by treatment with
aripiprazole in the hypothalamus. No significant changes were found in the expression
of all three sub-types of NRG1 isoforms in the hippocampus after long-term treatment
with three antipsychotic drugs.
Table 3.2 Significant changes in NRG1 isoform expression after 12-week treatment.
Prefrontal
Cingulate
Hippocampus
Hypothalamus
cortex
cortex
type I, III ,
type III,
Aripiprazole
type I ↓
40 kDa ↓
40 kDa ↓
type I, III ,
Haloperidol
40 kDa ↓
40 kDa ↓
Olanzapine
-

3.4.1

Brain Regional Differences of NRG1 Isoform Expression

The results of the present study have indicated that chronic treatment with
antipsychotics regulated NRG1 isoform expression in a region-specific manner. In the
PFC and in the hypothalamus, the effects of antipsychotic treatment were much greater
than those in the CG (only aripiprazole changed 40 kDa isoform in the CG); however,
there were no effects after all three antipsychotic treatments in the hippocampus. A
previous animal study showed alterations of NRG1 isoform expression in the rat PFC
and in the hippocampus (Wang et al., 2008), which were not completely consistent with
our findings. A human study conducted by Law et al. also showed the levels of mRNA
for NRG1-type I were changed in the PFC and the hippocampus in schizophrenia
patients (Law et al., 2006). Further, Parlapani reported that NRG1-type I expression was
altered in the PFC and in the hippocampus; the expression of NRG1-type II was also
changed in the PFC of schizophrenia patients (Parlapani et al., 2008). Therefore, first,
the results of the present study support the hypothesis that there are regional differences
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in the effects of antipsychotic treatment on the expression of NRG1 isoforms; secondly,
it is also evident that our study has shown remarkable differences from previous animal
study and human studies. However, due to limited evidence and the complicated
pharmaceutical properties of antipsychotics, the reasons for these changes remain
unknown. Furthermore, no previous study has measured NRG1 isoform expression in
the CG and the hypothalamus.

3.4.2

Treatment Duration may Influence NRG1 Isoform Expression

Two-way ANOVA analysis indicated that the effects of the factor “Period” were
significant on the expression of all three sub-types of NRG1 isoforms in all four brain
regions. As mentioned before, short-term antipsychotic treatments in general had
no/fewer effects. Only olanzapine and haloperidol significantly increased the expression
of NRG1-type III in the hippocampus and in the hypothalamus, respectively; whereas
long-term treatment with all these antipsychotic drugs was able to decrease NRG1
isoform expression. The present study partly confirmed the finding of previous studies
that worked on the short-term effects of antipsychotics. For example, short-term
treatments of haloperidol and risperidone could promote the expression of NRG1
isoforms; whereas clozapine could inhibit NRG1 isoform expression (Wang et al.,
2008). Further, NRG1 expression in human brain aggregates was increased by 3-week
treatment with clozapine, but not haloperidol (Chana et al., 2009). Additionally, NRG1
mRNA expression in PBLs of schizophrenia patients was significantly increased by 2week treatment with risperidone and quetiapine (Zhang et al., 2008). Thus, it can be
seen that the results of previous studies were partly consistent with the findings of the
present study. Therefore, further studies are required to explore the short-term effects of
antipsychotics on the expression of NRG1 isoforms.
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For long-term effects of antipsychotics, human studies have also shown conflicting
results. In human studies, patients have undergone various antipsychotic treatments
including typical and atypical antipsychotic treatments for very long periods (from
months to years). Hashimoto and colleagues reported that the expression of NRG1-type
I was increased and the expression of NRG1-type II was decreased in post-mortem
tissue of schizophrenia patients (Hashimoto et al., 2004). In addition, the levels of
mRNA for type I NRG1 were found to be increased both in the PFC and the
hippocampus in schizophrenia patients treated with various antipsychotics (Law et al.,
2006). Another study reported that NRG1 isoform I expression was decreased in the
prefrontal cortex and the hippocampus, whereas isoform II expression increased in the
anterior prefrontal cortex of schizophrenia patients (Parlapani et al., 2008). Furthermore,
Petryshen and colleagues (2005) found that the expression of NRG1-type I and type III
in PBLs increased in schizophrenia patients. It is apparent that the evidence from
previous studies conflicts with the results of the present study.

The discrepancy between results may be attributed to a number of factors. First, male
rats were used in Wang’s study (2008), whereas the present study used female rats.
Secondly, drug dosage and administration methods varied, for example, rats in the
present study were orally administered 0.3 mg/kg haloperidol, whereas Wang et al.
(2008) administered 1 mg/kg haloperidol intraperitoneally. Lastly, treatment duration
differed between studies, ie: 4 weeks (Wang et al., 2008) vs 1 and 12 weeks in the
present study.

It is worth noting that normal (healthy) animals were used in the present study. Due to
pathophysiological changes in various neurotransmitter systems in schizophrenia
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patients (Hashimoto et al., 2004; Law et al., 2006; Parlapani et al., 2008), differential
responses to antipsychotic treatment would occur compared to normal subjects.
Therefore, these different responses may contribute to inconsistencies between previous
reports and the present study. Thus, it is important for further studies to verify whether
antipsychotic-induced changes of NRG1 and ErbB4 expressions observed in this study
also occur in the animal models of schizophrenia.

In the present study, it is possible that the chronic antipsychotic treatment could
remarkably influence NRG1-ErbB4 signalling, causing decreases in the expression of
NRG1 isoforms. Thus, the alterations in NRG1 isoform expression may be the
consequence of adapting to the chronic antipsychotic treatment. However, the exact
molecular mechanisms remain unknown. Further studies are therefore needed to
investigate which receptor plays a key role in these antipsychotic-induced changes in
the expression of NRG1 isoforms.

3.4.3

Differential Effects of the Three Antipsychotic drugs on NRG1 Isoforms
Expression

The results of the present study showed that antipsychotic drugs with distinct receptor
binding properties had different effects on the expression of NRG1 isoforms.
Haloperidol and olanzapine showed very weak effects on protein expression in the 1week treatment groups; whereas aripiprazole did not affect the protein levels at all after
1-week treatment. This indicates that 1-week may be too short for antipsychotics to
exert their effects on NRG1 isoform expression.
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In the 12-week treatment groups, the effects exerted by the three antipsychotic
treatments were strong and distinctive. Twelve-week treatment with aripiprazole caused
the largest decreases in the expression of all NRG1 isoforms. Twelve-week treatment
with haloperidol exhibited fewer, but still strong, decreasing effects on protein
expression. However, olanzapine completely lost its influence on protein expression.
These differences may lie in the distinct receptor occupancies of antipsychotic drugs. As
described in Chapter 1, section 1.7 and Chapter 2, section 2.2.1, haloperidol is an
antagonist for the dopamine D2 receptor, but has low effects on other receptors (the
serotonin 5-HT2A,2C,1A receptors) (Ayd, 1978; Settle and Ayd, 1983). In addition,
olanzapine can act on multiple receptors, including moderately potent antagonism for
the dopamine D2 receptors, and highly potent antagonism for the serotonin 5-HT2A, 5HT2C, receptor (Mathews and David, 2007). Further, aripiprazole exhibits high affinity
dopamine D2 receptor partial agonism, and it is also a partial agonist for the serotonin 5HT1A receptor and an antagonist for the 5-HT2A receptor (Mace and Taylor, 2009;
Wood and Reavill, 2007). Therefore, it is possible that the dopamine D2 receptor
activity is associated with the regulation of NRG1 isoform expression, in which a high
affinity for the dopamine D2 receptor is important for regulating the expression of
NRG1 isoforms. This may explain why olanzapine did not show any significant effects
on NRG1 isoform expression after long-term treatment compared with the other two
drugs with high affinity for the dopamine D2 receptor. Additionally, it is also possible
that antipsychotic drugs (e.g. aripiprazole) with partial agonism for the dopamine D2
receptor may contribute to a stronger effect on the expression of NRG1 isoforms.
However, the exact molecular mechanisms are not clear. Furthermore, aripiprazole is
considered to be a functional selective drug (Urban et al., 2007), which may also
contribute to its strong effects on altering NRG1 isoform expression. However, the
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exact underlying mechanisms still need to be explored. Last, the effects of
antipsychotics on the serotonin 5-HT system may also impact the alterations in NRG1
isoform expression. The underlying molecular mechanisms, however, require
investigation.

3.5

Summary

In summary, this chapter showed the expression of the three sub-types of NRG1 in
various brain regions. Short-term treatment with antipsychotic drugs had few effects ─
only haloperidol and olanzapine increased the expression of NRG1-type III in the
hippocampus and the hypothalamus, respectively; whereas chronic treatments displayed
strong decreases in protein levels. These results are partly consistent with those of
previous studies, which may be due to different treatment periods, distinct antipsychotic
treatment, and complicated tissue sources. In the present study, aripiprazole induced the
largest decreases in NRG1 isoform expression in various brain regions. This may be
ascribed to the highest affinity for the dopamine D2 receptor of aripiprazole and its
partial agonism for the D2 receptor. However, the exact mechanisms remain unclear.
Further studies are required to investigate this interesting research area.
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CHAPTER 4: THE EFFECTS OF ANTIPSYCHOTICS ON THE EXPRESSION
OF ERBB4 RECEPTORS

4.1

Introduction

ErbB4 receptors are the receptors for NRG1 proteins. The ErbB4 receptor plays a
crucial role in the NRG1-mediating pathways that regulate a large number of functions
in the nervous system. Abnormalities of the ErbB4 receptor are considered to be
strongly implicated in the pathophysiology of schizophrenia. Evidence has shown that
NRG1-ErbB4 signalling was impaired in schizophrenia subjects including animals and
humans (for review: see Harrison and Law, 2006). In addition, expression of ErbB4
receptors was found to be abnormal in schizophrenia subjects and could be changed by
treatment with antipsychotic drugs (for details: see Chapter 1, section 1.8.2). In this
chapter, the effects of three antipsychotic treatments on the expression of ErbB4
receptors in various brain regions were investigated.

4.2
4.2.1

Methods and Materials
Animal Treatment and Tissue Preparation

All the materials and procedures have been described in Chapter 2, section 2.1 and 2.2.

4.2.2

Immunoblotting

All the materials and procedures for Immunoblotting ─ Western Blotting experiments
have been described in Chapter 2, section 2.4.2. Anti-ErbB4 (SC-283 Santa Cruz
Biotechnology) was diluted by 1:500. Based on pre-experiments, the exposure time to
Kodak BioMax film was four minutes. The other antibody (the secondary antibody and
β-actin antibody) used in this experiment has also been described in Chapter 2, section
2.4.2. The exposure time for β-actin antibody was twenty seconds.
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4.2.3

Quantification

In the present study, ErbB4 receptor expression was measured in all four brain regions
by using the immunoblotting technique. The protein of the ErbB4 receptor displayed up
to seven immunoreactive bands. Other studies using the SC-283 Santa Cruz ErbB4
antibody have also detected multiple bands in mouse, rat, and human brain tissue
(Bernstein et al., 2006; Mechawar et al., 2007; Savonenko et al., 2008; Thompson et al.,
2007). According to the manufacturer’s instruction, the 185 kDa band representing the
full length of the molecule of the ErbB4 receptor, was analysed.

4.2.4

Statistical Analysis

First, ErbB4 receptor protein levels data were corrected based on their corresponding βactin levels to control for sample-loading variations in protein concentration. Then the
expression data of ErbB4 receptors in each brain region was measured by two-way
ANOVA (Period × Treatment), respectively. Post-hoc multiple comparisons (the
Dunnet t test) followed, to compare each drug treatment group with the control. If the p
value from Dunnet t test was less than 0.05, ErbB4 receptor expression was considered
to be significantly changed by the antipsychotic treatment. Pearson Correlation was
used to analyse the relationship among the expression of NRG1 isoforms and ErbB4
receptors if they were significantly altered in the same brain region.

4.3

Results

Examples of the images of the Western blot experiment showing the expression of
ErbB4 receptors and β-actin are shown in Figure 4.1.
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Aripiprazolee

Haloperidol

Olanzaapine

Control

Figure 4.1 An examplee of images oof ErbB4 receptor expression.

4.3.1 Exxpression off ErbB4 Recceptors in th
he Prefrontaal Cortex
A two-waay ANOVA revealed a significantt effect of Period
P
(F1,488 = 30.827, p < 0.001))
on ErbB4 receptor ex
xpression inn the PFC, whereas
w
the effect of Trreatment diid not reachh
significancce (F3,48 = 0.345, p = 0.793). Ad
dditionally, there was significant interactionn
between Period
P
and Treatment
T
(F
F3,48 = 5.240, p = 0.005
5).

n indicated that 1-weeek treatmen
nt with halloperidol significantlyy
Post-hoc comparison
increased the protein
n expressionn of ErbB4 (+113%, p = 0.027) (FFigure 4.2). In the 12-week treattment, both
h aripiprazolle and halop
peridol treaatment decreeased the protein levell
of ErbB4 receptors (--58%, p = 00.033; -61%
%, p = 0.050
0, respectiveely). The an
nalysis alsoo
showed a trend towarrds a signifiicant differeence betweeen the olanzzapine treatment groupp
and the coontrol (-33%
%, p = 0.0966).
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Figure 4.22 The expresssion of ErbB
B4 receptorss in the preffrontal cortexx. *p<0.05 compared
c
too
control.

4.3.2 Exxpression off ErbB4 Recceptors in th
he Cingulatee Cortex
A two-waay ANOVA demonstratted that therre were no significant eeffects of Period
P
(F1,488
= 0.713, p = 0.405) or Treatm
ment (F1,488 = 0.153, p = 0.9277) on ErbB
B4 receptorr
expressionn in the CG
G. Further, there was no significcant interacction betweeen the twoo
factors (F3,48
= 0.803,, p = 0.501)).
3

s
differences in either the
t 1-weekk
As shownn in Figure 4.3, there were no significant
treatment groups or th
he 12-weekk treatment groups.
g
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Figure 4.3 The expresssion of ErbB44 receptors in
i the cingulaate cortex.

4.3.3 Exxpression off ErbB4 Recceptors in th
he Hippocam
mpus
A two-waay ANOVA showed siggnificant efffects of Period (F1,48 = 8.208, p = 0.008) andd
Treatmentt (F3,48 = 3.304,
3
p = 0.034) on the expresssion of ErrbB4 recep
ptors in thee
hippocamppus. Howev
ver, interacttion betweeen Period an
nd Treatmeent was nott significantt
(F3,48 = 1.3395, p = 0.2
264).

Post-hoc analysis
a
(Fiigure 4.4) ddisplayed th
hat there waas no signifi
ficant chang
ge in ErbB44
receptor expression
e
in the hipppocampus after 1-weeek treatmennt; howeveer, 12-weekk
treatment with aripiprrazole signiificantly red
duced the prrotein level (-43%, p = 0.024).
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Figure 4.44 The expreession of ErrbB4 recepto
ors in the hippocampus
h
s. *p<0.05 compared
c
too
control

4.3.4 Exxpression off ErbB4 Recceptors in th
he Hypothallamus
A trend toowards signiificance of P
Period (F1,448 = 3.198, p = 0.083) w
was revealed by a two-way ANO
OVA analysis on ErbB44 receptors in the hypothalamus. In addition
n, the effectt
of Treatment did not show signifficance (F3,48 = 0.621, p = 0.606), nor did thee interactionn
between Period
P
and Treatment
T
(F
F3,48 = 1.762, p = 0.175
5).

h aripiprazoole, the prottein level off
Figure 4.55 shows thatt after the 112-week treatment with
ErbB4 recceptors in th
he hypothallamus was significantly
s
y reduced (--57%, p = 0.031).
0
Thee
haloperidool treatmentt for 12 weeeks also teended to decrease the E
ErbB4 exprression, butt
not signifficantly (-46
6%, p = 0. 076). On th
he other haand, each 11-week drug
g treatmentt
showed noo significan
nt changes c ompared with the control.
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Figure 4.55 The expreession of Erb
rbB4 recepto
ors in the hy
ypothalamuss. *p<0.05 compared
c
too
control.

4.4

Corrrelation beetween the Expression
n of NRG1 Isoforms aand ErbB4 Receptors

Since thee expression
n of NRG
G1 isoformss and ErbB
B4 receptoors were concurrentlyy
changed inn the PFC and the hyppothalamuss after 12-w
week treatm
ment with an
ntipsychoticc
drugs, Peaarson Correlation tests were perfo
ormed to dettermine thee relationshiips betweenn
the expresssion of thee three sub-ttypes of NR
RG1 isoform
ms and the ErbB4 receeptor in thee
PFC; and between th
he expressiion of NRG
G1-type III, 40 kDa issoform and the ErbB44
halamus.
receptor inn the hypoth

Figure 4.66a shows a significant positive co
orrelation (r = 0.867, p = 0.000) between
b
thee
expressionn of NRG-ty
ype I and E
ErbB4 recep
ptors in the PFC
P after ch
chronic treattments withh
three antippsychotics. A significaant positivee correlation
n (r = 0.9199, p = 0.000
0) was alsoo
identified between th
he expressioon of 40 kD
Da isoform of
o NRG1 an
and ErbB4 receptors
r
inn
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the PFC after
a
long-term drug trreatment (F
Figure 4.6b). Furtherm
more the expression off
NRG1-typpe III was also positiveely correlateed with ErbB4 receptorr expression
n (r = 0.811,
p = 0.000)) (Figure 4.6
6c)

(a)

(bb)

(c)
Figure 4.66 Correlation
n between thhe expressio
on of (a) NR
RG1-type I, (b) 40 kDaa isoform off
NRG1 andd (c) NRG1-type III annd ErbB4 reeceptors in the
t prefrontaal cortex affter 12-weekk
treatment.

In the hyppothalamus, after 12-w
week treatmeent with anttipsychoticss, both 40 kDa
k isoform
m
(r = 0.6388, p = 0.015
5) (Figure 44.7a) and ty
ype III (r = 0.797, p = 0.001) (F
Figure 4.7b))
were founnd to be positively correlated with the expression of ErbB4
4 receptors,,
respectiveely.
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(a)

(b)

Figure 4.77 Correlation
n between thee expression of (a) 40 kD
Da isoform oof NRG1 and
d (b) NRG1-type III andd ErbB4 receeptors in the hypothalamu
us after 12-w
week treatmeent.

4.5

Disccussion

This expeeriment dem
monstrated tthe alteratio
on of ErbB4
4 receptor eexpression after short-term and long-term
l
trreatments w
with the three antipsychotic drugss in four braain regions..
This was the first tiime that ariipiprazole was
w investiigated to de
determine itts effect onn
ErbB4 recceptor expreession.

peridol significantly inncreased expression off
For the shhort-term trreatment grroup, halop
ErbB4 recceptors in the
t PFC; w
whereas arip
piprazole an
nd olanzapinne did not induce anyy
changes compared with
w the conttrols (Tablee 4.1). In th
he other threee brain reg
gions, theree
was no siggnificant change or trennd caused by
b short-term
m antipsychhotic treatmeent.
Table 4.1 Significant
S
changes in ErrbB4 recepto
or expression
n after 1-weekk treatment.
Prefrontal
Cing
gulate
Hippocampu
pus
Hypo
othalamus
cortex
corrtex
Aripiprrazole

-

-

-

-

Halopeeridol

ErbB4 ↑

-

-

-

Olanzaapine

-

-

-

-
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In the 12-week treatment groups, expression of ErbB4 receptors in the PFC was
inhibited by chronic treatment with aripiprazole and haloperidol (Table 4.2), and the 12week treatment with olanzapine also showed an apparent (but not significant) trend to
decrease the protein level of ErbB4 receptors in the PFC. In the hypothalamus, the
aripiprazole treatment for 12 weeks also significantly reduced ErbB4 receptor
expression compared with control; while the protein level was also decreased by the
haloperidol treatment, this change was not statistically significant. Moreover, none of
the three antipsychotic treatments showed alteration of ErbB4 receptor expression in the
CG or in the hippocampus.
Table 4.2 Significant changes in ErbB4 receptor expression after 12-week treatment.
Prefrontal
Cingulate
Hippocampus
Hypothalamus
cortex
cortex
Aripiprazole

ErbB4 ↓

-

-

ErbB4 ↓

Haloperidol

ErbB4 ↓

-

-

-

Olanzapine

-

-

-

-

Further, Pearson Correlation tests demonstrated that after 12-week treatment with the
three antipsychotic drugs, expression of the three sub-types of NRG1 isoforms was
positively correlated with ErbB4 receptor expression in the PFC. In addition, in the
long-term treatment groups, the expression of NRG1-type III and 40 kDa isoform were
positively correlated with expression of ErbB4 receptors in the hypothalamus.

4.5.1

Brain Regional Differences on the Expression of ErbB4 Receptors

The results of the present study indicate that the expression of ErbB4 receptors after
antipsychotic treatment might be related to treatments, periods and brain regions.
Previous studies showed that there could be different changes to the expression of
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ErbB4 receptors in various regions after treatment with antipsychotics. An animal study
reported that after 4-week administration to normal rats, haloperidol promoted the
expression of ErbB4 in the rat PFC; haloperidol, clozapine and risperidone also showed
this effect in the hippocampus (Wang et al., 2008). A post-mortem study also
demonstrated changes in expression of the ErbB4 receptor isoforms that contain the
CYT-1 domain in the dorsolateral PFC of schizophrenia patients (Silberberg et al.,
2006). In the present study, the effects of antipsychotic treatment on the expression of
ErbB4 also displayed brain regional differences ─ short-term treatment with haloperidol
showed significant effects on the expression of ErbB4 receptors in the PFC; chronic
treatment with aripiprazole significantly changed the protein level in all four brain
regions, and haloperidol did this in the PFC. However, no changes were found in the
CG and in the hippocampus. Therefore, the results of the present study were not
completely consistent with those of the previous study.

In addition, this was the first study to investigate ErbB4 receptor expression in the CG
and in the hypothalamus after a 12-week antipsychotic treatment. The results in the
present study should be validated in future studies.

4.5.2

ErbB4 Receptor Expression may be Changed by the Treatment Duration

The animal study of Wang et al. also demonstrated that short-term treatment with
haloperidol, clozapine and risperidone was able to increase the expression of ErbB4
receptors (Wang et al., 2008), which was partly replicated in the present study. However,
this increasing trend was not quite clear in the present study, only haloperidol increased
ErbB4 expression, but not olanzapine or aripiprazole. As discussed before in Section
3.4.2, the results of drug treatment could be affected by many factors, including
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treatment duration, dosage, administration method and gender of animal. Moreover, the
ErbB4 receptor isoforms containing the CYT-1 domain have been found to be increased
in schizophrenia patients (Silberberg et al., 2006), so long-term treatment with various
antipsychotic drugs could increase expression of ErbB4 receptors, which conflicts with
the findings of the present study. The pathophysiological changes on various
neurotransmitter systems in schizophrenia patients may affect the response of the ErbB4
receptor expression to antipsychotic treatment. However, the exact causes remain
unclear. Further studies are still needed to explore this area.

4.5.3

Differential Effects of the Three Different Antipsychotic Drugs on ErbB4
Receptor Expression

Similar to the results in relation to NRG1 isoforms, the results of the present study also
indicate that the changes in ErbB4 receptor expression may be related to the distinct
receptor binding properties of antipsychotic drugs. Similar conclusions may be drawn
that, first, 1-week might be too short for antipsychotics to exert their effects on ErbB4
receptor expression, since only haloperidol increased ErbB4 levels after 1-week
treatment; the other two drugs did not exert any effect. Secondly, also similar to the
situation with NRG1 expression after 12 weeks of antipsychotic treatment, the effects of
chronic antipsychotic treatment on the expression of ErbB4 receptors were stronger and
more distinctive than those in the 1-week treatment groups. Compared with the effects
of antipsychotic drugs on the expression of NRG1 isoforms, 12-week treatment with
aripiprazole also caused the largest decreases in the expression of ErbB4 receptors;
however, 12-week treatment with haloperidol exhibited fewer decreasing effects on
ErbB4 receptor expression; and olanzapine also showed very little influence on ErbB4
receptor expression. It is clear that the changes in the expression of ErbB4 receptors
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were correlated with the alteration of NRG1 isoform expression in each brain region,
displaying similar changing trends. These differences in the expression of ErbB4
receptors may also be interpreted in terms of the distinct pharmacological profile. High
affinity for the dopamine D2 receptor may be associated with decreased ErbB4 receptor
expression. The distinct pharmacological profile of aripiprazole, partial agonism for the
dopamine D2 receptor, may contribute to stronger effects on the expression of ErbB4
receptors; further, the functional selective actions of aripiprazole at the dopamine D2
receptor may also influence its effects on the expression of ErbB4 receptors. In addition,
the ways in which antipsychotics act on the serotonin 5-HT system may also impact the
alterations of ErbB4 receptor expression (for details: see section 5.2.2 in Chapter 5).
However, the underlying molecular mechanisms are not fully understood.

4.5.4

Relationship between NRG1-ErbB4 Expression and Long-term Antipsychotic
Treatments

When combined with the results in Chapter 3, it is apparent that antipsychotic
treatments exerted similar effects on the expression of NRG1 isoforms and ErbB4
receptors ─ short-term antipsychotic treatments could increase their expression, whereas
long-term antipsychotic treatments could decrease their protein levels. Pearson
Correlation analysis showed that the alterations of the expression of NRG1 isoforms
were highly correlated with the changes of ErbB4 receptor expression in the PFC and
the hypothalamus in long-term treatment groups. This may also suggest that in the
present study, NRG1-ErbB4 signalling was largely changed by the chronic
antipsychotic treatments, inducing consistent decreases in the expression of NRG1
isoforms and ErbB4 receptors. However, the study of Wang et al. showed inconsistent
changes between the expression of ErbB4 receptors and NRG1 isoforms after treatment
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with clozapine for 4 weeks (Wang et al., 2008). As schizophrenia patients are generally
administered antipsychotic treatment for an extended period of time, one possible
explanation for the lack of change in the NRG1-ErbB4 system reported by Wang et al.
(2008) in the treatment period of 4 weeks. It is possible that 4-week treatment period is
insufficient to induce changes in NRG1-ErbB4 expression. However, the exact
relationship between NRG1-ErbB4 expression and long-term antipsychotic treatment
requires further investigation.

4.5.5

Other ErbB4 Receptor Ligands may Affect NRG1-ErbB4 Expression

The previous studies have suggested that the ErbB4 receptor can not only be bound and
activated by NRG1, but also by NRG2 (Carraway et al., 1997; Chang et al., 1997),
NRG3 (Zhang et al., 1997) and NRG4 (Harari et al., 1999). Moreover, there are other
gene products that are agonists for the ErbB4 receptor, for example, heparin bindingEGF (HB-EGF) (Elenius et al., 1997), epiregulin (Shelly et al., 1998) and betacellulin
(Riese et al., 1996). Thus, it is possible that the proteins binding with ErbB4 receptors
may influence NRG1-ErbB4 signalling, inducing alteration in expression of ErbB4
receptors. An animal study showed haloperidol and clozapine were able to ameliorate
the behavioural abnormalities in HB-EGF knockout mice (Oyagi et al., 2009). However,
no study has linked the functional changes of HB-EGF with olanzapine and aripiprazole
treatments. Additionally, no study has explored whether, and how, the antipsychotic
treatments affect NRG2, NRG3, NRG4, epiregulin, and betacellulin. The roles of NRG2,
NRG3, NRG4, epiregulin, and betacellulin in regulating the expression of NRG1-ErbB4
are not clear. Therefore, further studies are required to answer these questions.
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4.6

Summary

In summary, this chapter showed that expression of ErbB4 receptors was changed in
various brain regions by administration of both typical and atypical antipsychotic drugs.
Administration of antipsychotic drugs regulated ErbB4 receptor expression in a drug
type- and brain region-specific manner. Furthermore, antipsychotic treatment may alter
NRG1-ErbB4 signalling, thus, displaying similar impacts on the expression of NRG1
isoforms and ErbB4 receptors. Further studies are required to explore the underlying
molecular mechanisms to uncover the exact relationship between antipsychotic
treatment and ErbB4 receptor expression.
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CHAPTER 5: OVERALL DISCUSSION AND RECOMMENDATIONS
The present study has examined the effects of 1-week and 12-week treatment with
aripiprazole, haloperidol and olanzapine on the expression of NRG1 isoforms and
ErbB4 receptors in the rat brain, respectively. This is the first study to investigate the
effects of 12-week antipsychotic treatments on the expression of NRG1 isoforms and
ErbB4 receptors. It is also the first study to explore how aripiprazole influences the
expression of NRG1 isoforms and ErbB4 receptors. In addition, this study is the first to
report the effects of antipsychotic treatments on the expression of NRG1 isoforms and
ErbB4 receptors in the CG and the hypothalamus. The main findings were that: (1)
compared with short-term treatments, chronic treatment with antipsychotic drugs
showed much stronger influences on the expression of NRG1 isoforms and its ErbB4
receptors; (2) their alterations after treatment with antipsychotics displayed regional
differences, for example, their alterations in the PFC and the hypothalamus were more
remarkable than those in the other two brain regions; and (3) chronic aripiprazole
treatments demonstrated stronger effects on the expression of NRG1 isoforms and
ErbB4 receptors than the other two drugs.

5.1

Summary of the Alterations in the Expression of NRG1 Isoforms and ErbB4
Receptors after Treatment with Three Antipsychotic Drugs

In the prefrontal cortex, after treatment with antipsychotics for 1 week, the expression
of NRG1 isoforms was not significantly affected; however, 12-week treatment with
aripiprazole and haloperidol reduced the expression of NRG1-type I, type III and 40
kDa isoforms. Additionally, after the 1-week treatments, only the haloperidol treatment
significantly increased the expression of ErbB4 receptors in the PFC; and after the 12-
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week treatment, aripiprazole and haloperidol inhibited the expression of ErbB4
receptors.

In the cingulate cortex, 1-week antipsychotic treatment did not significantly change
the expression of NRG1 isoforms; whereas, chronic treatment with aripiprazole reduced
the protein level of the NRG-type I isoform. There was no significant change in the
expression of ErbB4 receptors after short-term and long-term antipsychotic treatments
in the CG.

In the hippocampus, 1-week treatment with olanzapine promoted the expression of
NRG1-type I and type III isoforms; however, no significant change was observed in the
expression of all three sub-types of NRG1 isoforms after the three long-term
antipsychotic treatments. Further, there was no significant alteration in the expression of
ErbB4 receptors after 1-week and 12-week antipsychotic treatments in the hippocampus.

In the hypothalamus, short-term treatment with haloperidol increased the expression
of NRG-type III isoforms; chronic aripiprazole treatment reduced the expression of
NRG1-type III and 40 kDa isoform, and haloperidol also decreased 40 kDa isoform
expression in the hypothalamus. In addition, there was no significant change in the
expression of ErbB4 receptors after short-term antipsychotic treatments; but 12-week
aripiprazole treatment significantly reduced ErbB4 receptor expression in the
hypothalamus.

Correlations After long-term treatment with antipsychotic drugs, the expression of
each of the three sub-types of NRG1 isoforms was shown to be correlated with its
Page 70

ErbB4 receptors in the PFC. Moreover, the expression of NRG1-type III and 40 kDa
isoform was found to be correlated with the expression of ErbB4 receptors in the
hypothalamus in the 12-week treatment groups, which indicated alterations in the
NRG1-ErbB4 signalling pathways.

5.2

Overall Discussion and Recommendations

The findings of the present study suggest that aripiprazole and haloperidol may induce
alterations in the expression of NRG1 isoforms (including NRG1-type I, type III and 40
kDa isoform (possibly type II isoform)) and its ErbB4 receptors, whereas olanzapine
had fewer effects. The extent of their effects may be related to their pharmacological
properties. No evidence showed that antipsychotic drugs can directly bind or act on the
ErbB4 receptor. Instead, antipsychotics possess varied binding profiles to various
neurotransmitter receptors (DeLeon et al., 2004). Therefore, it is possible that the
expression of NRG1-ErbB4 in the present study was indirectly influenced by
antipsychotic drugs through various neurotransmitter receptors.

5.2.1

The Possible Role of the Dopamine D2 receptors

Various antipsychotic drugs possess distinct pharmacological actions on the dopamine
D2 receptors. For example, haloperidol displays high affinity dopamine D2 receptor
antagonism; olanzapine has moderate affinity dopamine D2 receptor antagonism; and
aripiprazole also possesses high affinity for the dopamine D2 receptors, but it is a D2
receptor partial agonist (DeLeon et al., 2004) (Figure 5.1). One study in our lab
examined mesolimbic and nigrostriatal dopaminergic transmission (including D2
receptor binding, mRNA expression of the D2 receptor and tyrosine hydroxylase mRNA
expression) in rats after treatment with these three antipsychotics and found that 12Page 71
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5.2.2

The Possible Role of the Serotonin 5-HT System

Besides the dopamine D2 receptor system, the antipsychotic drugs used in the present
study can also affect the serotonin 5-HT receptors (Figure 5.1), for example, olanzapine
has high affinity serotonin 5-HT2A,2C receptor antagonism, which could interact with its
dopamine D2 receptor antagonism to achieve its clinical efficacy (Mathews and David,
2007). In addition, aripiprazole displayed partial agonism for the serotonin 5-HT1A
receptors and antagonism for the 5-HT2A receptors (Jordan et al., 2002; Zhang et al.,
2006). However, haloperidol has very low affinity for the serotonergic receptors
(DeLeon et al., 2004). A previous study in our lab showed that 36-day treatment with
olanzapine in rats significantly increased 5-HT2A receptors mRNA expression, but
decreased 5-HT2C mRNA expression (Huang et al., 2006); however, 36-day treatment
with haloperidol in rats had no effect on changing 5-HT2A,2C receptor mRNA expression
(Huang et al., 2007). Furthermore, another study in our lab found that 1-week treatment
with aripiprazole increased 5-HT1A receptor binding density, and 1-week treatment with
olanzapine decreased 5-HT1A receptor binding density; however, the 12-week
aripiprazole and olanzapine treatments did not affect 5-HT1A receptor binding density;
additionally, the haloperidol treatment did not show any significant effect on 5-HT1A
receptor binding density after either 1 or 12 weeks of treatment (Han et al., 2009b).
These studies (Han et al., 2009b; Huang et al., 2006; Huang et al., 2007) indicated that
the 5-HT system could be influenced by short-term olanzapine treatments, but not longterm olanzapine treatments, probably through blocking the 5-HT1A receptors, which
may explain why only short-term treatment with olanzapine could affect NRG-ErbB4
expression in the present study. Furthermore, they also suggested that after chronic
antipsychotic treatments, the expression of NRG1-ErbB4 may not be affected by
antipsychotic treatments through the 5-HT system. However, no study has examined the
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5-HT2A,2C receptors after treatment with aripiprazole; further, the exact relationship
between the 5-HT system and NRG-ErbB4 expression is still obscure. Further studies
should explore the interactions between various neurotransmitter systems for a fuller
understanding of the mechanisms by which antipsychotics change the expression of
NRG1-ErbB4.

5.2.3

Brain Regional Differences in NRG1-ErbB4 Expression

The four brain regions examined in the present study showed different responses in
NRG1-ErbB4 expression to the antipsychotic treatments, which was probably due to the
distinct neural circuits in different brain regions. (1) In the present study, the expression
of NRG-ErbB4 in the PFC was more remarkable than in other brain regions. Studies
showed that dysfunction of the PFC in schizophrenia patients induced symptoms of
poor attention and conceptual disorganization (Servan-Schreiber et al., 1996) and
dysfunctions in cognitive processes such as executive functions and working memory
(Perlstein et al., 2001; Woo et al., 2007). The functions of the PFC are intricately
regulated by GABAergic and glutamatergic transmission that is affected by NRGErbB4 signalling (Woo et al., 2007). Thus, the results of the present study may add a
new line of evidence that schizophrenia symptoms, such as working memory deficits,
may be alleviated through regulating NRG1-ErbB4 signalling in the PFC with
antipsychotic treatments. (2) The effects on the expression of NRG1-ErbB4 in the
hypothalamus were also clearly observed. The hypothalamus connects to nearly every
part of the central nervous system, mainly regulating the autonomic and endocrine
systems (Williams et al., 2001). However, no study has examined the changes of
NRG1-ErbB4 expression in the hypothalamus in schizophrenia subjects. Therefore, the
findings of the present study may indicate that NRG1-ErbB4 signalling in the
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hypothalamus may be a potential future target for antipsychotic drugs to treat
schizophrenia symptoms. (3) The expression of NRG1-ErbB4 in the CG was not
notably altered. Since the present study is the first to investigate this area, it is possible
that the antipsychotic drugs may not directly influence the functions of NRG1-ErbB4
signalling in the CG to exert their clinical efficacy. (4) The effects of antipsychotics on
the expression of NRG1-ErbB4 in the hippocampus were also not remarkable, which is
contrary to some previous studies. Therefore, it is necessary to explore how
antipsychotic drugs affect NRG1-ErbB4 expression in the hippocampus in future
research. In addition, future studies are needed to explore how antipsychotics act in the
PFC, the hypothalamus and other brain regions to influence the expression of NRG1ErbB4.

5.2.4

Isoform-specific Differences on the Expression of NRG1

In the present study, the antipsychotic drugs showed different impacts on the expression
of specific sub-type of NRG1 isoform in certain brain regions. Therefore, the potential
changes in NRG1 mRNA transcription, splicing, translation or proteolytic cleavage of
precursor proteins induced by antipsychotic drugs are required to investigate in the
future. Additionally, future therapies may target a specific type of NRG1 isoforms to
treat schizophrenia symptoms.

Antipsychotic drugs can affect a wide range of GPCRs, including the dopamine,
serotonin, histamine, and muscarinic receptors (Mathews and David, 2007), therefore, it
is necessary to investigate how these GPCRs regulate specific isoforms of NRG1.
Moreover, NRG1-ErbB4 pathway is regulating a wide range of critical neuronal
functions in the nervous system, such as neuronal specification, neuronal migration and
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differentiation,

glial

development,

synapse

formation,

myelination,

synaptic

transmission, dendritic growth, and transcriptional regulation, (Harrison and Law, 2006;
Mei and Xiong, 2008; Stefansson et al., 2002), many of which are impaired in
schizophrenia. However, it is not clear whether these neuronal functions are associated
with specific isoforms of NRG1. Therefore, understanding how GPCRs affect the
NRG1 regulation of these neuronal functions may provide a clue for elucidating the
mechanisms of antipsychotic efficacy in treating schizophrenia symptoms.

5.2.5

Implications for the Future Personalised Medications

A clinic study reported that the schizophrenia patients with different NRG1 genotypes
could respond differently to typical antipsychotic drugs (Kampman et al., 2004). The
findings of the present study that aripiprazole and haloperidol can alter the expression of
NRG1-ErbB4 provide new evidence that schizophrenia patients with different NRG1
genotypes may respond differently to aripiprazole and haloperidol treatments. Therefore,
future studies are needed to explore whether the patients with different NRG1 genotypes
could have different responses to aripiprazole, olanzapine and other atypical
antipsychotic treatments. Understanding these changes and the underlying mechanisms
will be helpful in development of new personalised medications for schizophrenia
patients.
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